Welcome to our dedicated page for YS Biopharma Co., Ltd. Ordinary Shares news (Ticker: YS), a resource for investors and traders seeking the latest updates and insights on YS Biopharma Co., Ltd. Ordinary Shares stock.
YS Biopharma (YS) delivers innovative vaccines and biologics through its proprietary PIKA immunomodulating technology. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives shaping the company's global biopharmaceutical operations.
Access consolidated information on YS's research progress, including rabies vaccine trials, hepatitis B therapeutics, and manufacturing expansions. Our repository ensures you stay informed about critical updates without searching multiple sources.
Key content includes earnings reports, partnership announcements, trial result publications, and regulatory submissions. All materials maintain factual accuracy focus, adhering to financial disclosure standards.
Bookmark this page for streamlined tracking of YS Biopharma's advancements in next-generation vaccine development and international market strategies.
YS Biopharma Co., Ltd. (NASDAQ: YS) reports preliminary FY2023 revenues of approximately $103 million, reflecting a robust 30% year-over-year growth. Gross margin stands at over 76%, bolstered by strong vaccine sales amidst uncertain economic conditions. Cash and equivalents have increased to $53 million from $42.7 million a year prior. The company maintains approximately 93,058,197 ordinary shares outstanding.
CEO Dr. David Shao highlights the growing demand for their rabies vaccine, anticipating continued revenue growth as social activities resume post-pandemic. The results are preliminary and subject to audit, with caution against relying solely on these figures.
YS Biopharma (Nasdaq: YS) has announced positive interim results from its Phase II study of the PIKA recombinant COVID-19 Vaccine. The vaccine demonstrated superior immunogenicity compared to an inactivated COVID-19 vaccine, achieving statistical significance in both primary and secondary endpoints. Notably, the geometric mean titers (GMT) of neutralizing antibodies against the Omicron variant were significantly higher on Day 7 and Day 14 post-vaccination. The study, conducted across multiple countries, included 300 subjects in Phase II. No significant safety issues were reported, and the results are expected to support further development and eventual publication in peer-reviewed journals.
FAQ
What is the current stock price of YS Biopharma Co., Ltd. Ordinary Shares (YS)?
What is the market cap of YS Biopharma Co., Ltd. Ordinary Shares (YS)?
